Nearly one in five Americans lives with arthritis or another rheumatic condition. For patients, that often means years of trying different medications, monitoring side effects, and adhering to a strict treatment regimen. Even a temporary lapse in treatment risks allowing disease to progress or cause long-term disability.
Yet the insurers patients depend on to keep treatment affordable and reliable are increasingly making medicines harder to obtain instead.
Large insurers frequently design coverage policies to maximize their own profits even when it harms patients. These opaque tactics can raise costs, delay or deny necessary care, and even push patients away from medicines that are already working.
As the executive director of a national nursing organization focused on rheumatology care, I've seen firsthand how these barriers affect the nurses and patients we serve.
Consider prior authorization, which requires healthcare providers to obtain an insurer's approval before it will cover a prescribed medicine or treatment. Insurers argue these requirements prevent unnecessary costs. But in practice, they are often needlessly complex, imposing substantial burdens -- including hours of administrative work -- on nurses and doctors and delaying patient care.
More than nine in 10 physicians report that prior authorization delays patient access and contributes to harmful outcomes. Up to 80% say that the prior authorization process leads to frustration and exhaustion that can cause patients to abandon treatment entirely -- especially when their doctors and nurses lack the time to advocate for them consistently.
One study found that insurers required prior authorization for over 70% of infusions for rheumatology patients, even though they ultimately approved almost all of those requests. That puts patients at risk of treatment interruptions -- which can cause flare-ups, lower quality of life, and unnecessary complications and hospitalizations -- for no clear benefit.
Insurers also frequently use step therapy -- also known as "fail first" -- which requires patients to try other drugs before the insurer will cover the medicine their clinician initially prescribed. That can force patients to spend valuable time on medications that don't work for them, allowing their conditions to worsen before they can get the treatment they need.
Many patients are forced to repeat prior authorization or step therapy even after finding a treatment that works -- particularly when they switch plans. About 12% of arthritis patients who have experienced step therapy have gone through it at least five times in the last five years. And nearly four in 10 arthritis patients say they've had to go through prior authorization for their medicines each year for the last five years.
But the barriers don't end with coverage decisions. Patients also face significant challenges when it comes to the cost of their medicines.
The largest insurers are integrated with pharmacy benefit managers, or PBMs, which they use to negotiate drug prices and manage lists of covered drugs. The three largest PBMs process nearly 80% of prescriptions dispensed in the United States.
PBMs claim to lower patient costs. But their compensation is tied to drugs' list prices, which incentivizes them to steer patients toward more expensive medications, and they have no obligation to pass the discounts they negotiate through to patients. Additionally, insurers often base patients' cost-sharing on a drug's higher list price rather than its lower negotiated price.
For rheumatology patients, who often rely on expensive specialty medications, these tactics can contribute to much higher out-of-pocket costs.
Fortunately, some lawmakers in Congress have recognized these problems. Senate Democrats recently released an early version of their health agenda that identifies unnecessary coverage restrictions, lack of transparency, insurance consolidation, and vertical integration as issues in need of reform.
Now, Congress should turn those insights into action. Lawmakers should ensure that patients do not have to restart prior authorization for an already approved treatment when they switch plans within the same insurer. They should also pass the bipartisan Safe Step Act, which would allow patients to bypass step therapy if doctors determine the insurer's preferred treatment is not medically appropriate.
Congress should also rein in PBMs by increasing transparency, eliminating payment structures that incentivize selection of higher-priced medicines, and ensuring negotiated discounts reach patients at the pharmacy counter.
Rheumatology patients, and their doctors and nurses, work hard to keep their conditions under control. And they count on insurers to keep their care reliable and affordable.
Policymakers should make sure insurers hold up their end of the bargain, rather than making it harder for patients to get the treatments they need.
Sadie Larson is the executive director of the Rheumatology Nurses Society.